Clera Antipsychotic Science
Summary
TLDRThe script reveals a surprising discovery in neuroscience: all antipsychotic medications target a specific region in the brain, the caudate putamen, which is rich in dopamine type 2 receptors. These receptors are crucial for motor control and are also linked to psychological functions. The script delves into the molecular interaction between dopamine and antipsychotics like haloperidol and olanzapine, highlighting how they block dopamine receptors, leading to varying degrees of efficacy and side effects, including Parkinsonism and tardive dyskinesia.
Takeaways
- 🧠 The discovery of a common target in the brain for all antipsychotics was a significant revelation, contrary to the belief that they acted in various parts of the brain.
- 💊 Antipsychotic medications primarily target the type 2 dopamine receptor, which is abundant in the caudate putamen region of the basal ganglia, responsible for motor control.
- 🤔 Dopamine type 2 receptors are also found in areas associated with psychological functions, such as the cingulate gyrus, cerebral cortex, and nucleus accumbens.
- 🔍 At the molecular level, dopamine is released in pulses and binds to its receptors rapidly, with antipsychotics like haloperidol blocking this access and affecting dopamine transmission.
- 🆚 There is a competitive interaction between dopamine and antipsychotic drugs for receptor binding, with tightly bound drugs like haloperidol winning the competition.
- 💊 Haloperidol is a long-acting drug, with a dose of 10 milligrams lasting for days, which is beneficial for controlling psychotic symptoms but can lead to accumulation and side effects over time.
- 🚫 High blockade by haloperidol can cause extrapyramidal symptoms, such as Parkinsonism, elevated prolactin levels, amenorrhea, and tardive dyskinesia.
- 💊 Olanzapine is another antipsychotic effective at lower doses but can produce Parkinsonism and a risk of tardive dyskinesia at higher doses.
- 📈 The risk of weight gain is associated with olanzapine use, which is an important consideration when prescribing this medication.
- 🔄 The script emphasizes the importance of understanding the molecular interactions of antipsychotics with the brain's dopamine system to manage their therapeutic effects and side effects effectively.
Q & A
What was the surprising discovery about the common target of antipsychotics in the brain?
-The surprising discovery was that all antipsychotics have a common target in the brain, which is the Spartan in the brain. This was unexpected as it was previously believed that antipsychotics acted on many parts of the brain and various proteins and receptors.
How many types of dopamine receptors are there in the brain, and which one is targeted by antipsychotic medication?
-There are five types of dopamine receptors in the brain. Antipsychotic medication specifically targets the type 2 receptor.
In which part of the brain are the type 2 dopamine receptors predominantly located, and what is its primary function?
-Type 2 dopamine receptors are predominantly located in the caudate putamen in the basal ganglia of the brain, which is primarily responsible for motor control of the body, including the arms and legs.
Which brain regions are associated with psychological functions and also contain type 2 dopamine receptors?
-The cingulate gyrus, the cerebral cortex, and the nucleus accumbens are brain regions associated with psychological functions that also contain type 2 dopamine receptors.
What happens at the molecular level when dopamine is released by nerve cells?
-Dopamine is released by nerve cells at a rate of five times per second in great pulses. The molecule then travels to the receptor area, which is just 100 angstroms away, and binds to the receptor very quickly, potentially a million times a second.
How does haloperidol, an antipsychotic, affect the interaction between dopamine and its receptors?
-Haloperidol blocks access to the receptor by dopamine, creating a competition between the drug and the dopamine molecule. In this competition, haloperidol, being tightly bound, usually wins, resulting in partial blocking of dopamine transmission.
What is the difference in the way olanzapine blocks the dopamine receptor compared to haloperidol?
-While olanzapine also blocks the dopamine receptor, dopamine molecules can still out-compete some of the olanzapine, allowing for some modest transmission of dopamine.
How does the dosing of haloperidol affect its binding to the receptor and its duration in the body?
-Haloperidol is a tightly bound drug that comes off slowly. A dose of 10 milligrams per patient per day can stay in the body for a day or two or more, which is beneficial for controlling psychotic symptoms.
What are the potential long-term effects of continuous daily dosing of haloperidol?
-Continuous daily dosing of haloperidol can lead to an accumulation of the drug, causing tardive dyskinesia and extrapyramidal symptoms.
At what level of blockade by haloperidol does parkinsonism become a risk?
-Parkinsonism becomes a risk when there is more than 80% blockade by haloperidol.
What are some side effects associated with olanzapine use?
-Olanzapine can cause parkinsonism at doses above 20 or 30 milligrams per day, and there is a risk of tardive dyskinesia and weight gain.
Outlines
🧠 Dopamine Receptors and Antipsychotic Action
The script discusses the surprising discovery that all antipsychotic medications target a common brain region, the caudate putamen in the basal ganglia, which is rich in dopamine type 2 receptors. These receptors are crucial for motor control and are also found in areas associated with thinking and feeling. The script explains the molecular interaction between dopamine and antipsychotics, such as haloperidol and olanzapine, which block dopamine receptors, leading to a reduction in psychotic symptoms. However, long-term use can result in side effects like tardive dyskinesia and parkinsonism due to the high blockade of dopamine receptors.
Mindmap
Keywords
💡Spartan
💡Antipsychotics
💡Dopamine receptors
💡Caudate putamen
💡Basal ganglia
💡Cingulate gyrus
💡Cerebral cortex
💡Nucleus accumbens
💡Haloperidol
💡Olanzapine
💡Tardive dyskinesia
Highlights
The discovery that all antipsychotics target a common region in the brain, the caudate putamen in the basal ganglia, was a big shock.
Antipsychotics were previously thought to act on many parts of the brain, but this finding identified a single common target.
There are five types of dopamine receptors in the brain, but only the type 2 receptor is targeted by antipsychotic medication.
Type 2 dopamine receptors are abundant in the caudate nucleus and putamen, which are primarily involved in motor control.
Psychologically relevant dopamine type 2 receptors are also found in the cingulate gyrus, cerebral cortex, and nucleus accumbens, which are associated with thinking and feeling.
At the molecular level, dopamine is released in pulses 5 times per second and binds to receptors very quickly, potentially a million times per second.
Antipsychotics like haloperidol block dopamine's access to the receptor, creating a competition between the drug and the neurotransmitter.
Haloperidol is tightly bound and wins the competition with dopamine, partially blocking dopamine transmission.
Olanzapine also blocks the dopamine receptor, but dopamine molecules can still out-compete some of the olanzapine, allowing for some transmission.
Haloperidol has a long duration of action, with a dose of 10 milligrams lasting for days, which is beneficial for controlling psychotic symptoms.
However, long-term daily dosing of haloperidol can lead to the accumulation of the drug and cause tardive dyskinesia and extrapyramidal symptoms.
Tardive dyskinesia and extrapyramidal symptoms can occur when there is more than 80% blockade by haloperidol.
Olanzapine is effective at doses of 10-20 milligrams per day and can cause parkinsonism at higher doses.
There is a risk of tardive dyskinesia with olanzapine at doses above 20-30 milligrams per day.
Olanzapine can also cause weight gain as a side effect.
Transcripts
the idea that I could find one Spartan
in the brain which was the common target
of all antipsychotics came as a big
shock to everyone I was told that
antipsychotics acted in many many parts
of the brain many many proteins many
receptors and here I found one region
which was common to all the a different
antipsychotic there are five types of
dopamine receptors in the brain but the
one that is the target for
anti-psychotic medication is the type 2
receptor and the type 2 receptors are
very rich in the caudate putamen in the
basal ganglia of the brain the caudate
nucleus and the putamen and that has
primarily motor control of the body arms
and legs and then there are
psychologically located dopamine type 2
receptors found in the cingulate gyrus
and the cerebral cortex nucleus
accumbens all these mysterious parts of
the brain presumably associated with
thinking and feeling imagine if we could
shrink down to the size of a molecule of
dopamine or one of these first-line
antipsychotic agents what would we see
down there at the molecular level as the
dopamine is released by the dopamine
nerve cells at five times per second in
great pulses the dopamine molecule then
arrives at the receptor area just 100
angstroms away and it goes on and off
the receptor very very quickly perhaps
as many as a million times a second and
in the presence of an anti-psychotic
like halo peridot the access to the
receptor by dopamine is blocked so there
is a competition between halo paradol
and dopamine and in this case halo
paradol being tightly bound wins the
competition and dopamine transmission is
partly blocked
olanzapine also blocks the dopamine
receptor but the dopamine molecules are
still able to out-compete some of the
olanzapine so that there's some modest
transmission he'll a pair at all is a
tightly bound drug it comes off slowly
but it's dose at 10 milligrams per
patient per day stays on for a day or
two or three or more and that's good
news to control the psychotic
symptomatic G but over the years if that
dosing continues daily and weekly and
monthly then that accumulates and causes
tardive dyskinesia extrapyramidal
symptoms kick in when there's more than
80% blockade by halo peridot so that
it's relatively easy with halo peridot
as the dosing goes up to walk into the
parkinsonian range with parkinsonism
elevated prolactin emia Galacta RIA
amenorrhea and of course long-term
tardive dyskinesia olanzapine is
effective at 10 20 milligrams per
patient per day it can produce
parkinsonism above 20 or 30 milligrams
there is a risk of tardive dyskinesia
which has been reported and there is
weight gain
تصفح المزيد من مقاطع الفيديو ذات الصلة
Pharmacology - ANTIPSYCHOTICS (MADE EASY)
Antipsychotics Mnemonics (Memorable Psychopharmacology Lecture 4)
Drug Addiction and the Brain
ما لا تعرفه عن كلوزابكس اقراص | 6 اسئله تتكرر عن الكلوزابكس اقراص
Tolerance and withdrawal | Processing the Environment | MCAT | Khan Academy
Risk factors for drug use and drug abuse
5.0 / 5 (0 votes)